Cargando…
Use of Lesion Response Rate in Actinic Keratosis Trials
Complete patient clearance is often required by regulatory agencies for the approval of treatments for actinic keratosis (AK). However, an increasing number of clinicians have challenged the use of this measure in clinical practice and its interpretation. It has been argued that complete patient cle...
Autores principales: | Szeimies, Rolf-Markus, Atanasov, Petar, Bissonnette, Robert |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5120634/ https://www.ncbi.nlm.nih.gov/pubmed/27645828 http://dx.doi.org/10.1007/s13555-016-0145-2 |
Ejemplares similares
-
Efficacy Endpoints in Clinical Trials in Actinic Keratosis
por: Skov, Torsten, et al.
Publicado: (2018) -
Expert Recommendations on Facilitating Personalized Approaches to Long-term Management of Actinic Keratosis: The Personalizing Actinic Keratosis Treatment (PAKT) Project
por: MORTON, Colin, et al.
Publicado: (2023) -
A Review of MAL-PDT for the Treatment Strategy of Actinic Keratosis: Broader Clinical Perspectives Beyond the Data and Guideline Recommendations
por: Szeimies, Rolf-Markus, et al.
Publicado: (2023) -
Actinic Keratosis: Rationale and Management
por: Dodds, Annabel, et al.
Publicado: (2014) -
Optimal treatment of actinic keratosis
por: Goldenberg, Gary
Publicado: (2013)